Medicine Information

Imigra

Name: Imigra
Brand: Imigra

Tablet10 mgAntimigraine preparationsATC: N02CC01

Generic Name

Sumatriptan

Manufacturer

Square Pharmaceuticals Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
imigra 10 mg tablet	৳ 5.00	৳ 50.00

Description

Overview of the medicine

Sumatriptan is a medication primarily used for the acute treatment of migraine attacks, with or without aura, and cluster headaches. It belongs to the triptan class of drugs.

Uses & Indications

Acute treatment of migraine attacks with or without aura in adults

Acute treatment of cluster headache (often with injectable or nasal spray forms, oral may be used off-label for some cases)

Dosage

Adults

For migraine: Take 10 mg orally at the first sign of a migraine attack. If symptoms recur or a satisfactory response is not achieved, a second dose may be taken after at least 2 hours. Do not exceed 2 doses (20 mg total) in 24 hours. The typical oral doses are 25 mg, 50 mg or 100 mg; a 10 mg tablet would be considered a low dose and specific medical advice should be followed.

Elderly

Use with caution due to potential age-related decrease in renal or hepatic function and increased risk of cardiovascular events. Dosage adjustments may be considered based on individual response and tolerability.

Renal_impairment

No specific dose adjustment is generally required, but use with caution in patients with severe renal impairment due to limited experience.

How to Take

Take the tablet orally with water, as soon as migraine symptoms appear. Do not use it for prevention. The tablet should not be crushed, chewed, or split.

Mechanism of Action

Sumatriptan is a selective serotonin (5-HT1B/1D) receptor agonist. It works by causing vasoconstriction of cranial blood vessels, which are thought to be dilated during a migraine attack, and by inhibiting the release of neuropeptides, thereby alleviating migraine symptoms.

Pharmacokinetics

Onset

Oral: Effects typically begin within 30-60 minutes.

Excretion

Primarily renal (60% as inactive metabolite, 20% unchanged). Also excreted in feces.

Half life

Approximately 2-2.5 hours.

Absorption

Rapidly absorbed after oral administration. Bioavailability is about 15% due to first-pass metabolism.

Metabolism

Primarily hepatic, via monoamine oxidase-A (MAO-A) enzyme to an inactive indole acetic acid metabolite.

Side Effects

Contraindications

Ischemic heart disease (e.g., angina pectoris, history of myocardial infarction)
Cerebrovascular syndromes (e.g., stroke, transient ischemic attack)
Peripheral vascular disease
Uncontrolled hypertension
Severe hepatic impairment
Concomitant use with ergotamine-containing medications or other triptans
Concomitant use with MAO inhibitors or within 2 weeks of discontinuing MAO inhibitors
Hemiplegic or basilar migraine

Drug Interactions

SSRIs/SNRIs

Potential for serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, incoordination, nausea, vomiting, diarrhea). Use with caution, monitor for symptoms.

MAO Inhibitors

Concomitant use is contraindicated, as MAO-A inhibitors reduce sumatriptan clearance, leading to increased plasma levels and risk of toxicity. Do not use within 2 weeks of stopping MAO inhibitors.

Other Triptans

Concomitant use or use within 24 hours of another triptan is contraindicated due to potential for additive cardiovascular effects.

Ergotamine-containing drugs

Concomitant use or use within 24 hours is contraindicated due to additive prolonged vasoconstrictor effects.

Storage

Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.

Overdose

Symptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, cyanosis, respiratory depression, and salivation. Management is supportive, monitoring cardiac and respiratory function and managing symptoms for at least 12 hours. There is no specific antidote.

Pregnancy & Lactation

Pregnancy Category C: Animal studies have shown adverse effects on the fetus. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: Sumatriptan is excreted in breast milk. Caution should be exercised when administered to a nursing woman, or consider discarding breast milk for 12 hours after a dose.

Side Effects

Contraindications

Ischemic heart disease (e.g., angina pectoris, history of myocardial infarction)
Cerebrovascular syndromes (e.g., stroke, transient ischemic attack)
Peripheral vascular disease
Uncontrolled hypertension
Severe hepatic impairment
Concomitant use with ergotamine-containing medications or other triptans
Concomitant use with MAO inhibitors or within 2 weeks of discontinuing MAO inhibitors
Hemiplegic or basilar migraine

Drug Interactions

SSRIs/SNRIs

Potential for serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, incoordination, nausea, vomiting, diarrhea). Use with caution, monitor for symptoms.

MAO Inhibitors

Concomitant use is contraindicated, as MAO-A inhibitors reduce sumatriptan clearance, leading to increased plasma levels and risk of toxicity. Do not use within 2 weeks of stopping MAO inhibitors.

Other Triptans

Concomitant use or use within 24 hours of another triptan is contraindicated due to potential for additive cardiovascular effects.

Ergotamine-containing drugs

Concomitant use or use within 24 hours is contraindicated due to additive prolonged vasoconstrictor effects.

Storage

Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.

Overdose

Pregnancy & Lactation

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

10 tablets per blister pack30 tablets per blister pack

Shelf Life

Typically 2-3 years from the date of manufacture.

Availability

Pharmacies

Approval Status

Approved by major regulatory bodies

Patent Status

Generic available, original patent expired

WHO Essential Medicine

Yes

Clinical Trials

Extensive clinical trials have established the efficacy and safety of sumatriptan for the acute treatment of migraine. Post-marketing surveillance continues to monitor for rare adverse events and long-term safety.

Lab Monitoring

No routine laboratory monitoring is required for sumatriptan. However, for patients with cardiovascular risk factors, assessment of cardiovascular status including ECG and blood pressure monitoring is recommended before and during treatment.

Doctor Notes

Confirm migraine diagnosis before initiating sumatriptan therapy.
Counsel patients on appropriate use, including onset of action and maximum daily/24-hour dose limits.
Assess for cardiovascular risk factors and contraindications before prescribing.
Monitor for signs of serotonin syndrome, particularly if co-administered with SSRIs or SNRIs.

Patient Guidelines

Take Imigra 10 mg at the very first sign of a migraine headache.
Do not take this medicine to prevent a migraine; it's for acute treatment only.
Do not use if you have certain heart conditions, uncontrolled high blood pressure, or have recently had a stroke.
Inform your doctor about all medications you are taking, especially other migraine drugs or antidepressants.
Do not exceed the recommended dose and time interval between doses.

Missed Dose Advice

Sumatriptan is taken as needed for an acute migraine attack, not on a regular schedule. Therefore, there is no missed dose. If symptoms return after an initial dose, a second dose may be taken after 2 hours, but do not exceed the maximum daily limit.

Driving Precautions

Imigra 10 mg may cause dizziness, drowsiness, or fatigue, which could impair your ability to drive or operate machinery. Avoid such activities until you know how the medicine affects you.

Lifestyle Advice

Identify and avoid known migraine triggers (e.g., certain foods, stress, lack of sleep, strong odors).
Maintain a regular sleep schedule and eat meals at consistent times.
Stay hydrated and consider stress-reducing activities like yoga or meditation.